- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Others
Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market was valued at USD 12 billion in 2021 and poised to reach USD 16.3 billion by 2028 growing at a CAGR of 4.5% during the forecast period 2022 to 2028. Dipeptidyl Peptidase IV (DPP-IV) inhibitors also known as gliptins are oral anti-diabetic drugs, commonly used in the treatment of Type-2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP-1 by inhibition of the enzyme dipeptidyl peptidase IV. The effect of incretin is prolonged, improving the glycemic control by various mechanisms, initially by stimulating the insulin synthesis and secretion in a glucose-dependent manner and by reduction of glucagon secretion. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market are commonly prescribed for the patients with type 2 diabetes especially who are not responded well to sulfonyl ureas and metformin. Dipeptidyl Peptidase IV inhibitors decrease blood glucose levels and help in weight loss. The common adverse effects associated with DPP IV inhibitors is Pancreatitis. Increase in the prevalence and incidence of diabetic patients (According to the International Diabetes Federation, 7 million people are added every year to the pool of 246 million diabetics which increases to approximately 438 million by 2030. About 3.8 million People die each year from diabetes and even more, people die of other chronic diseases such as renal failure due to diabetes) expected to fuel the dipeptidyl peptidase IV inhibitors market.
Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market Summary
Study Period
2023-29
Base Year
2022
CAGR
4.5%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Dynamics
The excellent safety profile of dipeptidyl peptidase IV inhibitors, growing investments in the R&D activities, convenience benefit of being an oral medication, and acceptance of dipeptidyl peptidase IV inhibitors in oral antidiabetic drug class might fuel the dipeptidyl peptidase IV inhibitors market over the forecast period. Furthermore, favourable reimbursement policies for diabetes treatment, and low cost for dipeptidyl peptidase IV inhibitors expected to boost the dipeptidyl peptidase-IV inhibitors market over the forecast period. However, stringent regulatory policies, adverse effects associated with dipeptidyl peptidase IV inhibitors might hamper the dipeptidyl peptidase IV inhibitors market growth over the forecast period.
Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market Regional Analysis
North-America Got Significant Share
Geographically, dipeptidyl peptidase IV Inhibitors market is in booming stage in nature with several local and international players operating in the market. Launching of new products, approvals from various regulatory authorities such as U.S. Food and Drug Administration (U.S. FDA), acquisitions & mergers, and collaborations are some key strategies followed by various pharmaceutical companies for increasing their share in dipeptidyl peptidase IV inhibitors market. For instance, in March 2013, Otsuka obtains marketing approval in Japan for Onglyza tablets to treat Type 2 Diabetes. In April 2013, Takeda and Sanofi sign co-promotion agreement to expand the reach of diabetes treatment Alogliptin in China. Similarly, in February 2014, AstraZeneca completed the acquisition of Bristol-Myers Squibb share of the global diabetic alliance. Apart from this, in May 2011, Boehringer Ingelheim GMBH, and Eli Lilly and Co. announced that the U.S. Food and Drug Administration (FDA) has approved Tradjen (linagliptin) tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. In June 2011, the Tradjen was approved by European Medicines Agency (EMEA) in the Europe.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Dipeptidyl Peptidase Iv Dpp Iv Inhibitors Market Segmentation
Drug Type
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary
2. Global Dipeptidyl Peptidase IV Inhibitors Market Introduction
   2.1. Global Dipeptidyl Peptidase IV Inhibitors Market – Taxonomy
   2.2. Global Dipeptidyl Peptidase IV Inhibitors Market –Definitions
      2.2.1. Drugs
      2.2.2. Distribution Channel
3. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics
   3.1. Drivers
   3.2. Restraints
   3.3. Opportunities/Unmet Needs of the Market
   3.4. Trends
   3.5. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Factors Impact Analysis
   3.6. Global Dipeptidyl Peptidase IV Inhibitors Market – Regulations
      3.6.1. US
      3.6.2. Europe
      3.6.3. Japan
   3.7. Global Dipeptidyl Peptidase IV Inhibitors Market – Product Pipeline Analysis
4. Global Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024
   4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
   4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
   4.3. Market Oppurtunity Analysis
5. Global Dipeptidyl Peptidase IV Inhibitors Market, By Drugs, 2013 - 2017 and Forecast, 2018 - 2024
   5.1. Sitagliptin
      5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.1.3. Market Opportunity Analysis
   5.2. Vildagliptin
      5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.2.3. Market Opportunity Analysis
   5.3. Saxagliptin
      5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.3.3. Market Opportunity Analysis
   5.4. Linagliptin
      5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.4.3. Market Opportunity Analysis
   5.5. Others
      5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.5.3. Market Opportunity Analysis
6. Global Dipeptidyl Peptidase IV Inhibitors Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024
   6.1. Hospital Pharmacies
      6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      6.1.3. Market Opportunity Analysis
   6.2. Retail Pharmacies
      6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      6.2.3. Market Opportunity Analysis
   6.3. On-line Pharmacies
      6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      6.3.3. Market Opportunity Analysis
7. Global Dipeptidyl Peptidase IV Inhibitors Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024
   7.1. North America
      7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.1.3. Market Opportunity Analysis
   7.2. Europe
      7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.2.3. Market Opportunity Analysis
   7.3. Asia-Pacific
      7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.3.3. Market Opportunity Analysis
   7.4. Latin America
      7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.4.3. Market Opportunity Analysis
   7.5. Middle East and Africa
      7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.5.3. Market Opportunity Analysis
   7.6. Global Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel, and Region, 2018 – 2024
8. North America Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   8.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      8.1.1. Sitagliptin
      8.1.2. Vildagliptin
      8.1.3. Saxagliptin
      8.1.4. Linagliptin
      8.1.5. Others
   8.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      8.2.1. Hospital Pharmacies
      8.2.2. Retail Pharmacies
      8.2.3. On-line Pharmacies
   8.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      8.3.1. US
      8.3.2. Canada
   8.4. North America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   8.5. North America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
9. Europe Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   9.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      9.1.1. Sitagliptin
      9.1.2. Vildagliptin
      9.1.3. Saxagliptin
      9.1.4. Linagliptin
      9.1.5. Others
   9.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      9.2.1. Hospital Pharmacies
      9.2.2. Retail Pharmacies
      9.2.3. On-line Pharmacies
   9.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      9.3.1. Germany
      9.3.2. UK
      9.3.3. France
      9.3.4. Spain
      9.3.5. Italy
      9.3.6. Russia
      9.3.7. Poland
      9.3.8. Rest of Europe
   9.4. Europe Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   9.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
10. Asia-Pacific Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   10.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      10.1.1. Sitagliptin
      10.1.2. Vildagliptin
      10.1.3. Saxagliptin
      10.1.4. Linagliptin
      10.1.5. Others
   10.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      10.2.1. Hospital Pharmacies
      10.2.2. Retail Pharmacies
      10.2.3. On-line Pharmacies
   10.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      10.3.1. Japan
      10.3.2. China
      10.3.3. India
      10.3.4. ASEAN
      10.3.5. Australia & New Zealand
      10.3.6. Rest of Asia-Pacific
   10.4. Asia-Pacific Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   10.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
11. Latin America Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   11.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      11.1.1. Sitagliptin
      11.1.2. Vildagliptin
      11.1.3. Saxagliptin
      11.1.4. Linagliptin
      11.1.5. Others
   11.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      11.2.1. Hospital Pharmacies
      11.2.2. Retail Pharmacies
      11.2.3. On-line Pharmacies
   11.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      11.3.1. Brazil
      11.3.2. Mexico
      11.3.3. Argentina
      11.3.4. Venezuela
      11.3.5. Rest of Latin America
   11.4. Latin America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   11.5. Latin America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
12. Middle East and Africa Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   12.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      12.1.1. Sitagliptin
      12.1.2. Vildagliptin
      12.1.3. Saxagliptin
      12.1.4. Linagliptin
      12.1.5. Others
   12.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      12.2.1. Hospital Pharmacies
      12.2.2. Retail Pharmacies
      12.2.3. On-line Pharmacies
   12.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      12.3.1. Gulf Cooperation Council (GCC) Countries
      12.3.2. Israel
      12.3.3. South Africa
      12.3.4. Rest of MEA
   12.4. MEA Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   12.5. MEA Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
13. Competition Landscape
   13.1. Strategic Dashboard of Top Market Players
   13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      13.2.1. AstraZeneca Plc. (UK)
      13.2.2. Boehringer Ingelheim GmbH (Germany)
      13.2.3. Eli Lilly and Company (U.S.)
      13.2.4. Merck & Co, Inc. (U.S.)
      13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)
      13.2.6. Novartis AG (Switzerland)
      13.2.7. Takeda Pharmaceutical Company Limited (Japan)
      13.2.8. Sanofi (France)
      13.2.9. Bristol-Myers Squibb (U.S.)
      13.2.10. GlaxoSmithKline Plc. (U.K.)
      13.2.11. Pfizer, Inc. (U.S.)
      13.2.12. Otsuka Holdings Co. Ltd. (Japan)
      13.2.13. Ornamed Pharmaceutical, Inc. (Israel)
      13.2.14. Dr. Reddy’s Laboratories, Ltd. (India)
      13.2.15. Novo Nordisk A/S (Denmark)
14. Research Methodology
15. Key Assumptions and Acronyms
- AstraZeneca Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co, Inc. (U.S.)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Novartis AG (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Sanofi (France)
- Bristol-Myers Squibb (U.S.)
- GlaxoSmithKline Plc. (U.K.)
- Pfizer, Inc. (U.S.)
- Otsuka Holdings Co. Ltd. (Japan)
- Ornamed Pharmaceutical, Inc. (Israel)
- Dr. Reddy’s Laboratories, Ltd. (India)
- Novo Nordisk A/S (Denmark)